We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Durect and Voyager Pharmaceutical have completed enrollment for the recently
approved study for the DURIN-based leuprolide acetate product candidate for
Alzheimer's disease under development by the parties (the DURIN-leuprolide implant).
Sanofi-aventis has announced preliminary results of two large prospective trials
evaluating the safety and efficacy of Eloxatin-based regimens in the treatment
of metastatic colorectal cancer.
Cell Therapeutics is on track to report results in late March or early April
from the Xyotax pivotal trial in non-small cell lung cancer (NSCLC), known as
STELLAR 3.
Sonus Pharmaceuticals has announced that the FDA has granted an orphan-drug
designation to its lead oncology candidate, Tocosol Paclitaxel, for the treatment
of nonsuperficial urothelial cancer.
The first high-resolution analysis of the key feature that controls the activation
of genes on human chromosomes was reported today in the journal Cell, by researchers
from the Broad Institute of MIT and Harvard and Affymetrix.
According to a two-year head-to-head study published in the European Journal
of Internal Medicine, patients with Type 2 diabetes showed reduced incidences
of major hypoglycemia when using NovoLog Mix 70/30 versus biphasic human insulin
30 (Novolin 70/30) (0 percent versus 10 percent) with comparable efficacy.
Novolog Mix 70/30, a dual-action insulin analog that does not contain NPH
insulin, is more effective than insulin glargine in helping people with Type
2 diabetes who are new to insulin therapy achieve targeted A1C levels, according
to a study published in the February issue of Diabetes Care.
The FDA has accepted an investigational new drug (IND) application from Manhattan
Pharmaceuticals for the initiation of the human clinical trials required for
FDA approval of Propofol Lingual Spray (Propofol LS).